StockData
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc. (INBX) stock

INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$74.18−3.48 (-4.48%)

Close on Nov 17, 2026Market cap $1.09BP/E –Yield –

Earnings

Inhibrx Biosciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 18, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$2.00M
EPS, Q3 FY2026
-$2.46
-$2.28 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Inhibrx Biosciences's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 18, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 13, 2026after the close$2.00M–-$2.46Release
Q2 FY2026ended Jun 30, 2026Aug 13, 2026after the close––-$2.34Release
Q1 FY2026ended Mar 31, 2026May 14, 2026after the close––-$2.15Release
Q4 FY2025ended Dec 31, 2025Mar 19, 2026after the close––-$2.11Release
Q3 FY2025ended Sep 30, 2025Nov 14, 2025after the close––-$2.28Release
Q2 FY2025ended Jun 30, 2025Aug 13, 2025after the close$1.30M+1200.0%-$1.85Release
Q1 FY2025ended Mar 31, 2025May 14, 2025after the close––-$2.80Release
Q4 FY2024ended Dec 31, 2024Mar 17, 2025after the close$100.00K–-$3.09Release
Q3 FY2024ended Sep 30, 2024Nov 14, 2024after the close––-$2.84Release
Q2 FY2024ended Jun 30, 2024Aug 13, 2024after the close$100.00K–$125.48Release
Q1 FY2024ended Mar 31, 2024May 9, 2024after the close–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Inhibrx Biosciences has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Inhibrx Biosciences puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Inhibrx Biosciences filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. Update
  5. Results
  6. Update
  7. Update
  8. Results
  9. Update
  10. Update
  11. Update
  12. Update
  13. Results
  14. Update
  15. Update

See a number that looks wrong?